サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：組換えデオキシリボ核酸（rDNA）技術の世界市場の2028年までの予測 - 地域別、構成要素別（クローニングベクター、発現システム）、用途別（食品・飲料、農業、治療薬）　
市場調査レポート
商品コード
1064140

組換えデオキシリボ核酸（rDNA）技術の世界市場の2028年までの予測 - 地域別、構成要素別（クローニングベクター、発現システム）、用途別（食品・飲料、農業、治療薬）　

Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Forecasts to 2028 - Global Analysis By Component (Cloning Vector, Expression System), Application (Food & Beverages, Agriculture, Therapeutics) and By Geography
出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
組換えデオキシリボ核酸（rDNA）技術の世界市場の2028年までの予測 - 地域別、構成要素別（クローニングベクター、発現システム）、用途別（食品・飲料、農業、治療薬）　
出版日: 2022年08月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の組換えデオキシリボ核酸（rDNA）技術の市場規模は、2021年の1,557億9,000万米ドルから2028年には3,016億7,000万米ドルに達し、予測期間中にCAGRで9.9％の成長が予測されています。

当レポートでは、世界の組換えデオキシリボ核酸（rDNA）技術の市場について調査分析し、市場概要、市場動向分析、地域別の市場分析などについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 製品分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界の組換えデオキシリボ核酸（rDNA）技術市場：構成要素別

  • クローニングベクター
    • ヒト人工染色体（HAC）
    • 酵母人工染色体（YAC）
    • 細菌人工染色体（BAC）
    • コスミド
    • プラスミド
    • ファージ
  • 発現システム
    • 哺乳類細胞
    • 原核細胞
    • バクテリア
    • 酵母
    • バキュロウイルス/昆虫

第6章 世界の組換えデオキシリボ核酸（rDNA）技術市場：製品別

  • 医療
    • 治療薬
    • ワクチン
    • ヒトタンパク質
    • 遺伝子編集
    • 細胞および遺伝子治療
    • モノクローナル抗体
    • 組換えタンパク質薬
  • 非医療
    • 遺伝子組換え作物
    • 特殊化学品
    • 遺伝子組換え作物

第7章 世界の組換えデオキシリボ核酸（rDNA）技術市場：用途別

  • 食品・飲料
  • 農業
  • 治療薬
  • ヘルスケアと病気
    • 人間
    • 動物
  • 環境

第8章 世界の組換えデオキシリボ核酸（rDNA）技術市場：エンドユーザー別

  • バイオテクノロジーおよび製薬企業
  • 診断研究所
  • 学術および政府研究機関
  • 生化学産業

第9章 世界の組換えデオキシリボ核酸（rDNA）技術市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他

第10章 主な発展

  • 契約、パートナーシップ、コラボレーション、JV
  • 買収と合併
  • 新製品の発売
  • 拡張
  • その他の重要な戦略

第11章 企業プロファイル

  • Novartis AG
  • GlaxoSmithKline plc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Pfizer Inc.
  • Thermo Fisher Scientific, Inc.
  • Biogen Inc.
  • Biocon Limited
  • Novo Nordisk A/S
  • Merck KGaA
  • Amgen Inc.
  • Boehringer Ingelheim
  • Chiron Corporation
  • Genscript Biotech
  • Horizon Discovery Group plc
  • Monsanto Company
  • Profacgen
図表

List of Tables

  • Table 1 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Component (2020-2028) ($MN)
  • Table 3 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cloning Vector (2020-2028) ($MN)
  • Table 4 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human Artificial Chromosome (HAC) (2020-2028) ($MN)
  • Table 5 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Yeast Artificial Chromosome (YAC) (2020-2028) ($MN)
  • Table 6 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Bacterial Artificial Chromosome (BAC) (2020-2028) ($MN)
  • Table 7 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cosmid (2020-2028) ($MN)
  • Table 8 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Plasmid (2020-2028) ($MN)
  • Table 9 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Phage (2020-2028) ($MN)
  • Table 10 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Expression System (2020-2028) ($MN)
  • Table 11 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Mammalian Cells (2020-2028) ($MN)
  • Table 12 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Prokaryotic Cells (2020-2028) ($MN)
  • Table 13 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Bacteria (2020-2028) ($MN)
  • Table 14 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Yeast (2020-2028) ($MN)
  • Table 15 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Baculovirus / Insect (2020-2028) ($MN)
  • Table 16 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Product (2020-2028) ($MN)
  • Table 17 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Medical (2020-2028) ($MN)
  • Table 18 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Therapeutic Agent (2020-2028) ($MN)
  • Table 19 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Vaccine (2020-2028) ($MN)
  • Table 20 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human Protein (2020-2028) ($MN)
  • Table 21 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Gene Editing (2020-2028) ($MN)
  • Table 22 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Cell and Gene Therapy (2020-2028) ($MN)
  • Table 23 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Monoclonal Antibodies (2020-2028) ($MN)
  • Table 24 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Recombinant Protein Drugs (2020-2028) ($MN)
  • Table 25 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Non-Medical (2020-2028) ($MN)
  • Table 26 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Genetically Modified Crops (2020-2028) ($MN)
  • Table 27 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Specialty Chemicals (2020-2028) ($MN)
  • Table 28 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biotech Crops (2020-2028) ($MN)
  • Table 29 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Application (2020-2028) ($MN)
  • Table 30 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Food & Beverages (2020-2028) ($MN)
  • Table 31 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Agriculture (2020-2028) ($MN)
  • Table 32 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Therapeutics (2020-2028) ($MN)
  • Table 33 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Healthcare & Disease (2020-2028) ($MN)
  • Table 34 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Human (2020-2028) ($MN)
  • Table 35 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Animal (2020-2028) ($MN)
  • Table 36 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Environment (2020-2028) ($MN)
  • Table 37 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By End User (2020-2028) ($MN)
  • Table 38 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biotechnology and Pharmaceutical Companies (2020-2028) ($MN)
  • Table 39 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Diagnostic Laboratories (2020-2028) ($MN)
  • Table 40 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Academic & Government Research Institutes (2020-2028) ($MN)
  • Table 41 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Outlook, By Biochemical Industry (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC21757

According to Stratistics MRC, the Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market is accounted for $171.21 billion in 2022 and is expected to reach $301.67 billion by 2028 growing at a CAGR of 9.9% during the forecast period. Recombinant DNA technology is a process in which creation and manipulation of the DNA sequences are in a specific order. This is resulting in the production of genetically modified organisms and products. Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals.

DNA testing represented 44 percent of the global forensic technology market and was worth 4.95 billion U.S. dollars. Digital forensic technology currently represents around 30 percent of the market, around the same as ballistic forensic technology, but is forecast to exceed the DNA testing market in size by 2022.

Market Dynamics:

Driver:

Rising demand from various industries

Many industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied.

Restraint:

Risk associated with gene therapy

The global recombinant DNA technology market might face major restraints due to the risk associated with gene therapy. Another major restraint can be the stringent regulation for the approval of the product in various regions.

Opportunity:

Growth of genetic testing

In the North American and Western European regions, the genetic testing market grows larger, spreading its hands to many remote areas. Therefore, this can bring more opportunities for the service providers and companies to make the tests more affordable. Along with that, the global Recombinant DNA Technology Market is trying to enter the untapped regions to bring lucrative opportunities.

Threat:

Ethical considerations

The use of genetic modification technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and environment, scientific and ethical concerns vary in a discipline-specific manner.

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the market studied, as it increased the demand for recombinant DNA technology in the development of therapeutics and diagnostics. For instance, in November 2020, a research paper published in the United States National Library of Medicine named "Recombinant vaccines for COVID-19" stated that the recombinant COVID-19 vaccine has the capability to overcome limitations and the safety concerns associated with other vaccines. Many COVID-19 vaccines have been manufactured by several companies.

The expression system segment is expected to be the largest during the forecast period

Expression systems captured the largest share owing to the ongoing developments for efficient protein expression and for its further isolation on a large scale. Majorly used expression systems are mammalian, bacterial, insects, and yeast. The development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed to the significant share of mammalian expression systems. In addition, ongoing research studies to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years.

The agriculture segment is expected to have the highest CAGR during the forecast period

In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing a widespread adoption.

Region with largest share:

North America is projected to hold the largest market share owing to the substantial number of biopharmaceutical manufacturing participants which are headquartered in the U.S. The presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology has also driven the regional growth. For instance, this country witnessed the 1st FDA approval for U.S. gene therapy treatment. The treatment was developed for leukemia, as a result of a collaboration between the University of Pennsylvania and Novartis Corp. This, in turn, is anticipated to nurture the implementation of rDNA techniques in the region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the presence of low-cost manufacturing centers in the Asian economies, such as China. Japan is recognized as one of the world's largest per capita importers of food and feed developed using modern biotechnology tools. Japan's regulatory system for GE crops continues to improve. Moreover, there is no significant trade barrier in Japan to hamper GE products export from western countries. As a result, Asia Pacific is expected to emerge as the fastest-growing regional market.

Key players in the market

Some of the key players profiled in the Recombinant Deoxyribonucleic Acid (rDNA) Technology Market include Novartis AG, GlaxoSmithKline plc., Sanofi SA, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., Thermo Fisher Scientific, Inc., Biogen Inc., Biocon Limited, Novo Nordisk A/S, Merck KGaA, Amgen Inc., Boehringer Ingelheim, Chiron Corporation, Genscript Biotech, Horizon Discovery Group plc, Monsanto Company, and Profacgen.

Key developments:

In January 2022: Pfizer and Beam entered exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases. Four-year research collaboration combines Pfizer's deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam's leadership in base editing and mRNA/LNP delivery technologies.

In July 2020: GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK's existing mRNA capabilities with CureVac's integrated mRNA platform.

Components Covered:

  • Cloning Vector
  • Expression System

Products Covered:

  • Medical
  • Non-Medical

Applications Covered:

  • Food & Beverages
  • Agriculture
  • Therapeutics
  • Healthcare & Disease
  • Environment

End Users Covered:

  • Biotechnology and Pharmaceutical Companies
  • Diagnostic Laboratories
  • Academic & Government Research Institutes
  • Biochemical Industry

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Component

  • 5.1 Introduction
  • 5.2 Cloning Vector
    • 5.2.1 Human Artificial Chromosome (HAC)
    • 5.2.2 Yeast Artificial Chromosome (YAC)
    • 5.2.3 Bacterial Artificial Chromosome (BAC)
    • 5.2.4 Cosmid
    • 5.2.5 Plasmid
    • 5.2.6 Phage
  • 5.3 Expression System
    • 5.3.1 Mammalian Cells
    • 5.3.2 Prokaryotic Cells
    • 5.3.3 Bacteria
    • 5.3.4 Yeast
    • 5.3.5 Baculovirus / Insect

6 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Product

  • 6.1 Introduction
  • 6.2 Medical
    • 6.2.1 Therapeutic Agent
    • 6.2.2 Vaccine
    • 6.2.3 Human Protein
    • 6.2.4 Gene Editing
    • 6.2.5 Cell and Gene Therapy
    • 6.2.6 Monoclonal Antibodies
    • 6.2.7 Recombinant Protein Drugs
      • 6.2.7.1 Human Growth Hormone
      • 6.2.7.2 Blood Factors
      • 6.2.7.3 Colony Stimulating Factors
      • 6.2.7.4 Erythropoietin
      • 6.2.7.5 Fusion Proteins
      • 6.2.7.6 Interferon
      • 6.2.7.7 Insulin
  • 6.3 Non-Medical
    • 6.3.1 Genetically Modified Crops
    • 6.3.2 Specialty Chemicals
    • 6.3.3 Biotech Crops

7 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Application

  • 7.1 Introduction
  • 7.2 Food & Beverages
  • 7.3 Agriculture
  • 7.4 Therapeutics
  • 7.5 Healthcare & Disease
    • 7.5.1 Human
    • 7.5.2 Animal
  • 7.6 Environment

8 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By End User

  • 8.1 Introduction
  • 8.2 Biotechnology and Pharmaceutical Companies
  • 8.3 Diagnostic Laboratories
  • 8.4 Academic & Government Research Institutes
  • 8.5 Biochemical Industry

9 Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novartis AG
  • 11.2 GlaxoSmithKline plc.
  • 11.3 Sanofi SA
  • 11.4 F. Hoffmann-La Roche Ltd
  • 11.5 Eli Lilly and Company
  • 11.6 Pfizer Inc.
  • 11.7 Thermo Fisher Scientific, Inc.
  • 11.8 Biogen Inc.
  • 11.9 Biocon Limited
  • 11.10 Novo Nordisk A/S
  • 11.11 Merck KGaA
  • 11.12 Amgen Inc.
  • 11.13 Boehringer Ingelheim
  • 11.14 Chiron Corporation
  • 11.15 Genscript Biotech
  • 11.16 Horizon Discovery Group plc
  • 11.17 Monsanto Company
  • 11.18 Profacgen